UBS downgraded Merus (MRUS) to Neutral from Buy with a price target of $97, up from $72, after the company agreed to be acquired by Genmab (GMAB) is an all-cash transaction valued at $8.0B, or $97 per share. The firm sees limited overlap with Genmab’s existing pipeline.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Merus downgraded to Market Perform from Outperform at BMO Capital
- Merus downgraded to Equal Weight from Overweight at Barclays
- Merus downgraded to Market Perform from Outperform at LifeSci Capital
- Balanced Hold Rating on Genmab’s Acquisition of Merus Amid Valuation and Strategic Fit Concerns
- Merus downgraded to Neutral from Buy at Guggenheim